- Direction
- Unknown
- Own history
- —
- Peers
- 37th
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTADC Therapeutics SA's latest supported as-filed period reports revenue of $18.6M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -63.36% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 3.04% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 26.47% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -136.39% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 93.20% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 3.0%; Operating margin moved 10772 bp higher; Operating income increased 42.4%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 13.5%; SBC / revenue moved 1440 bp higher.
2 evidence-backed componentsFree-cash-flow proxy changed +51.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ADCT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000950103-26-015465SEC ↗10-QAug 13, 2026Period Jun 30, 20260001628280-26-056711SEC ↗8-KAug 13, 2026Period Aug 13, 20260000950103-26-012287SEC ↗4Jul 2, 2026Period Jun 30, 20260001628280-26-047036SEC ↗4Jul 2, 2026Period Jun 30, 20260001628280-26-047034SEC ↗4Jul 2, 2026Period Jun 30, 20260001628280-26-047033SEC ↗4Jul 2, 2026Period Jun 30, 20260001628280-26-047031SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026Filed Jul 2, 2026 | Zaki MohamedChief Medical Officer | Grant Or AwardDirect | 213,900 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 24.42% · OPTIONAL
Operating cash flow changed +51.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed -31.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed +151.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +33.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +42.4% from the comparable as-filed period.
Total assets changed -13.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000950103-26-010195